Search Results
Search for other papers by Ryoko Yamamoto in
Google Scholar
PubMed
Search for other papers by Tomoko Minamizaki in
Google Scholar
PubMed
Search for other papers by Yuji Yoshiko in
Google Scholar
PubMed
Search for other papers by Hirotaka Yoshioka in
Google Scholar
PubMed
Search for other papers by Kazuo Tanne in
Google Scholar
PubMed
Search for other papers by Jane E Aubin in
Google Scholar
PubMed
Search for other papers by Norihiko Maeda in
Google Scholar
PubMed
-resistant rickets suggest the existence of additional phosphaturic factor(s). Recently, intensive studies of several such putative factors (e.g. matrix extracellular phosphoglycoprotein, dentin matrix protein 1 (DMP1), and fibroblast growth factor 23 (FGF23) have
Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
Search for other papers by Claire L Wood in
Google Scholar
PubMed
Search for other papers by Rob van ‘t Hof in
Google Scholar
PubMed
Search for other papers by Scott Dillon in
Google Scholar
PubMed
Search for other papers by Volker Straub in
Google Scholar
PubMed
Search for other papers by Sze C Wong in
Google Scholar
PubMed
Search for other papers by S Faisal Ahmed in
Google Scholar
PubMed
Search for other papers by Colin Farquharson in
Google Scholar
PubMed
established pharmacological intervention proven to stabilise muscle strength for a finite period of time ( Manzur et al. 2008 , Moxley et al. 2010 , Birnkrant et al. 2018 ). The side-effects of GC, however, are well recognised, with growth retardation
Search for other papers by Graham W Aberdeen in
Google Scholar
PubMed
Search for other papers by Jeffery S Babischkin in
Google Scholar
PubMed
Search for other papers by Gerald J Pepe in
Google Scholar
PubMed
Search for other papers by Eugene D Albrecht in
Google Scholar
PubMed
growth factor (VEGF) has a well-established role in promoting angiogenesis in the adult, i.e. the formation and proliferation of capillaries ( Ferrara 1999 , Dvorak 2000 , Wagner 2011 ), and estrogen stimulates VEGF expression in many estrogen receptor
Search for other papers by David E Maridas in
Google Scholar
PubMed
Search for other papers by Victoria E DeMambro in
Google Scholar
PubMed
Search for other papers by Phuong T Le in
Google Scholar
PubMed
Search for other papers by Kenichi Nagano in
Google Scholar
PubMed
Search for other papers by Roland Baron in
Google Scholar
PubMed
Search for other papers by Subburaman Mohan in
Google Scholar
PubMed
Search for other papers by Clifford J Rosen in
Google Scholar
PubMed
Introduction IGF signaling is a crucial pathway controlling muscle, fat and bone growth and is regulated by 6 binding proteins, IGFBP1–6. The IGF-binding proteins can enhance or inhibit IGF action locally ( Gustafsson et al . 1999 , Tahimic
Department of Child Health, University of Arizona College of Medicine, Phoenix, Arizona, USA
Search for other papers by J Bryce Ortiz in
Google Scholar
PubMed
Search for other papers by Sebastian Tellez in
Google Scholar
PubMed
Department of Biology and Biochemistry, University of Bath, Bath, United Kingdom
Search for other papers by Giri Rampal in
Google Scholar
PubMed
Search for other papers by Grant S Mannino in
Google Scholar
PubMed
Search for other papers by Nicole Couillard in
Google Scholar
PubMed
Search for other papers by Matias Mendez in
Google Scholar
PubMed
Search for other papers by Tabitha R F Green in
Google Scholar
PubMed
Search for other papers by Sean M Murphy in
Google Scholar
PubMed
Search for other papers by Rachel K Rowe in
Google Scholar
PubMed
remains unknown. In juveniles, activation of the growth hormone (GH) axis results in linear body growth and changes in body size and composition ( Blakemore et al. 2010 ). This physical growth and increased height are linked to high levels of GH
Search for other papers by Shiao Y Chan in
Google Scholar
PubMed
Search for other papers by Laura A Hancox in
Google Scholar
PubMed
Search for other papers by Azucena Martín-Santos in
Google Scholar
PubMed
Search for other papers by Laurence S Loubière in
Google Scholar
PubMed
Search for other papers by Merlin N M Walter in
Google Scholar
PubMed
Search for other papers by Ana-Maria González in
Google Scholar
PubMed
Search for other papers by Phillip M Cox in
Google Scholar
PubMed
Search for other papers by Ann Logan in
Google Scholar
PubMed
Search for other papers by Christopher J McCabe in
Google Scholar
PubMed
Search for other papers by Jayne A Franklyn in
Google Scholar
PubMed
School of Clinical and Experimental Medicine, Department of Pathology, Fetal Medicine Centre, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
Search for other papers by Mark D Kilby in
Google Scholar
PubMed
Introduction Intrauterine growth restriction (IUGR) describes the failure of a fetus to attain its genetically determined growth potential, with the most common underlying etiology being uteroplacental failure associated with abnormal placental
Search for other papers by Valentina Pampanini in
Google Scholar
PubMed
Search for other papers by Daniela Germani in
Google Scholar
PubMed
Search for other papers by Antonella Puglianiello in
Google Scholar
PubMed
Search for other papers by Jan-Bernd Stukenborg in
Google Scholar
PubMed
Search for other papers by Ahmed Reda in
Google Scholar
PubMed
Search for other papers by Iuliia Savchuk in
Google Scholar
PubMed
Search for other papers by Kristín Rós Kjartansdóttir in
Google Scholar
PubMed
Dipartimento Pediatrico Universitario Ospedaliero ‘Bambino Gesù’ Children’s Hospital – Tor Vergata University, Rome, Italy
Search for other papers by Stefano Cianfarani in
Google Scholar
PubMed
Search for other papers by Olle Söder in
Google Scholar
PubMed
Introduction Adverse conditions during fetal life, such as low nutrient and/or oxygen supply from the placenta, can lead to intrauterine growth restriction (IUGR) and low birth weight. Besides affecting body growth, a suboptimal intrauterine
Search for other papers by Stuart A Lanham in
Google Scholar
PubMed
Search for other papers by Dominique Blache in
Google Scholar
PubMed
Search for other papers by Richard O C Oreffo in
Google Scholar
PubMed
Search for other papers by Abigail L Fowden in
Google Scholar
PubMed
Department of Biological and Medical Sciences, Oxford Brookes University, Oxford, UK
Search for other papers by Alison J Forhead in
Google Scholar
PubMed
Introduction Growth and development of long bones during late gestation are important for the normal functioning of the neonatal skeleton, especially in precocial species like sheep that stand and are mobile from birth. In normal and adverse
Search for other papers by K A Staines in
Google Scholar
PubMed
Search for other papers by A S Pollard in
Google Scholar
PubMed
Search for other papers by I M McGonnell in
Google Scholar
PubMed
Search for other papers by C Farquharson in
Google Scholar
PubMed
Search for other papers by A A Pitsillides in
Google Scholar
PubMed
Introduction The transition of cartilage to bone is the basis by which all long bones form. This transition is tightly regulated to ensure both permissive foetal development through endochondral ossification and postnatal longitudinal growth at the
St Mary’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
Search for other papers by Colin P Sibley in
Google Scholar
PubMed
adaptation to pregnancy, the timing of parturition, matching of supply with demand for nutrients by the fetus to enable normal growth ( Sferruzzi-Perri & Camm 2016 ) and indeed control of placental development itself. It is therefore not surprising that